Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies, and vaccines. Co.'s pipeline of product candidates includes: ALT-801, which is designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis; HepTcell, which is an immunotherapeutic for patients infected with the hepatitis B virus; NasoShield, which is an anthrax vaccine designed to provide protection after a single intranasal administration; NasoVAX, which is a recombinant intranasal vaccine that is being developed for seasonal and pandemic use; and AdCOVID, which is a single-dose, intranasal vaccine to protect against COVID-19. The ALT stock yearly return is shown above.
The yearly return on the ALT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|